{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"124-444-452-213-984","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"124-444-452-213-984"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":10806,"type":"PATENT","title":" Technion-Israel Institute of Technology - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":1908,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8271,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: \" Technion Israel Inst Techno\"; \"Techni* Israel Inst* Techno*\"
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 4
Search Applicants and Owners separately: \" Technion Israel Inst Techno\"; \"Techni* Israel Inst* Techno*\"
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 4
(a) obtaining a first sample of breast tumor tissue from a subject;\n
(b) obtaining a second sample of breast tumor tissue, which is non-metastatic; and\n
(c) determining that a tissue level and/or an activity level of a polypeptide set forth in SEQ ID NO: 2 is higher in the first breast tumor tissue sample than in the second breast tumor tissue sample;\n
thereby determining that the tumor from which the first sample was derived is metastatic."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein said determining in step (c) is effected by an immunological detection method and/or an RNA detection method."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein said determining in step (c) is effected by an enzymatic activity detection method."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 2, wherein said determining in step (c) is effected by the immunological detection method, which is selected from the group consisting of a radio-immunoassay (RIA), an enzyme linked immunosorbent assay (ELISA), a Western blot analysis, and an immunohistochemical analysis."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 2, wherein said determining in step (c) is effected by the RNA detection method, which is selected from the group consisting of a Northern blot analysis, an RNA in situ hybridization stain, an RT-PCR analysis, and an in situ RT-PCR stain."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 3, wherein said enzymatic activity detection method is selected from the group consisting of a cytochemical stain, an in vitro activity assay, and an activity gel."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 2, wherein the samples in step (c) are contacted with an antibody to LOR-1, such that LOR-1 in one or both of the samples forms a complex with the antibody, and the antibody-LOR-1 complex is detected."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 2, wherein the samples in step (c) are contacted with a nucleic acid probe homologous to the LOR-1 gene, such that LOR-1 mRNA in one or both of the samples forms hybrids with the probe, and the hybrids are detected."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 2, wherein the samples in step (c) are contacted with an antibody raised against LOR-1."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 7, wherein the samples in step (c) are contacted with an antibody raised against LOR-1."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 9, wherein the LOR-1 is human LOR-1."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 10, wherein the LOR-1 is human LOR-1."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["A method of determining that a breast tumor is metastatic or invasive, the method comprising:\n
(a) obtaining a sample of breast tumor tissue from a subject; and\n
(b) determining a tissue level and/or an activity level of a polypeptide set forth in SEQ ID NO: 2 in the breast tumor tissue sample;\n
wherein a higher tissue level and/or activity level of said polypeptide, compared with that of a non-metastatic breast tumor tissue sample, indicates that the tumor from the subject is metastatic or invasive."],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 13, wherein said determining in step (b) is effected by an immunological detection method and/or an RNA detection method."],"number":14,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 13, wherein said determining in step (b) is effected by an enzymatic activity detection method."],"number":15,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 14, wherein said determining in step (b) is effected by the immunological detection method, which is selected from the group consisting of a radio-immunoassay (RIA), an enzyme linked immunosorbent assay (ELISA), a Western blot analysis, and an immunohistochemical analysis."],"number":16,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 14, wherein said determining in step (b) is effected by the RNA detection method, which is selected from the group consisting of a Northern blot analysis, an RNA in situ hybridization stain, an RT-PCR analysis, and an in situ RT-PCR stain."],"number":17,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 15, wherein said enzymatic activity detection method is selected from the group consisting of a cytochemical stain, an in vitro activity assay, and an activity gel."],"number":18,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 14, wherein the sample in step (b) is contacted with an antibody to LOR-1, such that LOR-1 in the sample forms a complex with the antibody, and the antibody-LOR-1 complex is detected."],"number":19,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 14, wherein the sample in step (b) is contacted with a nucleic acid probe homologous to the LOR-1 gene, such that LOR-1 mRNA in the sample forms hybrids with the probe, and the hybrids are detected."],"number":20,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 14, wherein the sample in step (b) is contacted with an antibody raised against LOR-1."],"number":21,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 19, wherein the sample in step (b) is contacted with an antibody raised against LOR-1."],"number":22,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 21, wherein the LOR-1 is human LOR-1."],"number":23,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 22, wherein the LOR-1 is human LOR-1."],"number":24,"annotation":false,"title":false,"claim":true},{"lines":["A method of determining that a breast tumor is metastatic, the method comprising:\n
(a) assaying a tissue sample of the breast tumor for a tissue level and/or an activity level of a polypeptide set forth in SEQ ID NO: 2; and\n
(b) determining that the tissue level and/or the activity level is higher in the breast tumor tissue sample than in a non-metastatic breast tumor tissue sample,\n
thereby determining that the assayed tumor is metastatic."],"number":25,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 25, wherein the determining in step (b) is effected by an immunological detection method and/or an RNA detection method."],"number":26,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 25, wherein the determining in step (b) is effected by an enzymatic activity detection method."],"number":27,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 26, wherein the sample is contacted with an antibody to LOR-1, such that LOR-1 in the sample forms a complex with the antibody, and the antibody-LOR 1 complex is detected."],"number":28,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 26, wherein the sample is contacted with a nucleic acid probe homologous to the LOR-1 gene, such that LOR-1 mRNA in the sample forms hybrids with the probe, and the hybrids are detected."],"number":29,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 26, wherein the sample is contacted with an antibody raised against LOR-1."],"number":30,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 28, wherein the sample is contacted with an antibody raised against LOR-1."],"number":31,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 30, wherein the LOR-1 is human LOR-1."],"number":32,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}